Background <p>Simlukafusp alfa (FAP-IL2v) was engineered to preferentially activate CD8+ T and natural killer (NK) cells in tumor microenvironments overexpressing fibroblast activation protein (FAP). Checkpoint inhibitors combined with antiangiogenic agents are standard therapy for metastatic renal cell carcinoma (mRCC), which overexpresses FAP. Here, we explored the efficacy, safety, and pharmacodynamic effects of FAP-IL2v in combination with atezolizumab with or without…
Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study
Journal for ImmunoTherapy of Cancer | | Perez-Gracia, J. L., Mellado, B., Hansen, A. R., Alonso-Gordoa, T., Gomez-Roca, C., Lovendahl Eefsen, R., Negrier, S., Suarez, C., Lee, J.-L., Hussain, A., Pedrazzoli, P., Moreno, V., Rodriguez-Vida, A., Sosman, J. A., Waddell, T., Bedke, J., Park, S. H., Sznol, M., Spychaj, L., Andersson, E., Julien-Laferriere, A., Cheng, W.-Y., Watson, C., Silva, A. P., Heichinger, C., Staedler, N., Sleiman, N., Dejardin, D., Boetsch, C., Evers, S., Vardar, T., Ardeshir-Tandon, C., Dorado Perez, J., Charo, J., Keshelava, N., Kraxner, A., Teichgräber, V., Powles, T.
Topics: blood-cancer, kidney-cancer, cervical-cancer, immunotherapy, clinical-trials, new-technology, research
Read the full article at Journal for ImmunoTherapy of Cancer